Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology. The trial did not meet its primary endpoint as the addition of the immunotherapy agent atezolizumab to chemotherapy and radiation did not significantly improve survival for those with limited-stage SCLC. However, twice-daily radiation therapy was associated with improved survival in this population.

Researchers have developed a capsule-based method that makes it possible to analyse the same cell through multiple experimental steps. The technology overcomes a long-standing limitation in cell research and could open new ways to study disease mechanisms at the single-cell level.

A pioneering research-industry partnership has used advances in indoor farming technology to grow pea shoots fortified with Vitamin B12, opening an exciting route to market for farmers and addressing a major public health need.

 A bone-like composite developed at EPFL uses naturally occurring enzymes to accelerate mineralization through an energy-efficient, room-temperature process. The strong, lightweight material shows promise for bone repair applications.

Researchers from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), in collaboration with the Lunenfeld-Tanenbaum Research Institute at Sinai Health in Toronto, Canada, have achieved a major breakthrough in regenerative medicine. The team has genetically engineered human stem cells that can ‘cloak’ themselves to evade immune rejection, while carrying a built-in kill switch to prevent tumour formation. This innovation opens the door to a safe, off-the-shelf source of cells and tissues, potentially transforming treatment for conditions such as Parkinson’s disease, diabetes, heart failure, and spinal cord injuries, without the need for lifelong immune suppression.